Metformin Hydrochloride Extended-Release Tablets Recalled for NDMA Impurity
The Harvard Drug Group is recalling Metformin Hydrochloride Extended-Release Tablets due to potential NDMA impurity levels above established limits.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II. Per the rubric, FDA Class II recalls are assigned a severity score of 4 (Severe), particularly when involving significant chemical impurities like NDMA.
Plain-English summary
The Harvard Drug Group is recalling 1,906 cartons of Metformin Hydrochloride Extended-Release Tablets, USP, 500 mg. The product is distributed in 100-tablet unit dose cartons (10 x 10) and is available by prescription only. The specific lot number is T-02134, with an expiration date of 09/2020.
The recall was initiated due to a Current Good Manufacturing Practice (CGMP) deviation involving the potential presence of the impurity Nitrosodimethylamine (NDMA) above established levels. The product was manufactured by Apotex, Inc., in Toronto, Ontario, Canada, for Apotex Corp. in Weston, FL, and distributed by Major Pharmaceuticals in Livonia, MI.
The recall is classified as Class II by the FDA. The distribution pattern is listed as Nationwide USA. Consumers and healthcare providers should stop using the affected product and contact their healthcare provider or pharmacist for guidance on alternative treatment options.
The recalled product
- Product
- Metformin Hydrochloride Extended-Release Tablets, USP, 500 mg, 100 Tablets (10 x 10) unit dose cartons, Rx only, Manufactured by: Apotex, Inc., Toronto, Ontario, Canada, Manufactured for: Apotex Corp. Weston, FL, Distributed by: Major Pharmaceuticals, Livonia, MI 48152 NDC 00904
- Manufacturer
- The Harvard Drug Group
- Category
- Drug — Prescription Medication
- Hazard
- Affected units
- 1,906
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot T-02134
- exp 09/2020
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · The Harvard Drug Group
See all →- ModerateTramadol Hydrochloride Tablets Recalled Due to Inadequate Blister Packaging Seal
FDA (Drugs) · 2023-07-05
- ModerateGabapentin tablets recalled due to product mixup with foreign tablet
FDA (Drugs) · 2023-05-17
- HighCarbidopa and Levodopa Tablets Recalled for Inadequate Blister Packaging Seal
FDA (Drugs) · 2023-03-08
- ModeratehydrALAZINE HCl Tablets 10 mg Recalled for Failed Impurity Specifications
FDA (Drugs) · 2022-03-23
- ModeratePaliperidone Extended-Release Tablets Recalled for Failed Dissolution
FDA (Drugs) · 2022-03-16
Same hazard · ndma impurity
See all →- SeverePreferred Pharmaceuticals Recalls Metformin HCl Extended Release Tablets
FDA (Drugs) · 2021-05-26
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-02-10
- SevereNostrum Recalls Metformin Hydrochloride Extended-Release Tablets Due to NDMA Impurity
FDA (Drugs) · 2021-01-20
- SevereDenton Pharma Recalls Metformin Hydrochloride Tablets Due to NDMA Impurity
FDA (Drugs) · 2020-11-11
- SevereDirect Rx Recalls Metformin Hydrochloride Extended Release Due to NDMA Impurity
FDA (Drugs) · 2020-11-11